Chimeric antigen receptor T cell (CAR-T) is a novel cancer immunotherapy, but it priced over a million yuan, so it has not been included in National Reimbursement Drug List (NRDL), resulting in its poor affordability. Under the background of multi-level healthcare security system, a small number of commercial health insurance companies in China have first explored the inclusion of CAR-T products in their coverage, which has reduced the burden of patients to a certain extent. The paper selected two mainstream commercial health insurance products, Urban Customized Commercial Health Insurance (UCCHI) and Million Medical Insurance product, as analysis objects. Furthermore, this paper, taking into account international experience and the development needs of Chinese commercial insurance, summarized the current coverage situation of CAR-T products, and proposed to optimize the design of commercial insurance products in four aspects: high premium, high benefit, long term and close connection, in order to provide better coverage for CAR-T products and other high-value innovative drugs with "good efficacy, high cost and uncertain population".
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |